Apogen Biotechnologies: Accelerator's ApoGen nets new biochem leaders, plus an additional $4M to target cancer resistance

ApoGen raised $4 million with a new investment from Merck KGaA's M Ventures, upping its fundraising total to $11 million, while bringing on Stephen Gwaltney to be its VP of chemistry and Peter de Vries as senior director of biology.